Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
73,686,767
-
Share change
-
+1,647,808
-
Total reported value
-
$1,861,792,917
-
Put/Call ratio
-
79%
-
Price per share
-
$25.27
-
Number of holders
-
172
-
Value change
-
-$10,935,353
-
Number of buys
-
90
-
Number of sells
-
83
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q4 2024
As of 31 Dec 2024 Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) had 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 73,686,767 shares of stock of the company.
Largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, BlackRock, Inc., Kynam Capital Management, LP, FMR LLC, VANGUARD GROUP INC, EVENTIDE ASSET MANAGEMENT, LLC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, Bellevue Group AG, and Point72 Asset Management, L.P..
This table shows 172 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.